Microtransplantation Outcomes for Older AML Patients in a Single-Center Study

Juan Liu's dataset contains clinical results from a single-center study of 29 patients aged 60 years or older with newly diagnosed acute myeloid leukemia (AML). The data covers patients treated with microtransplantation between April 2008 and June 2021, with a median follow-up of 148.5 months. It includes endpoints such as complete remission rates, overall survival, leukemia-free survival, relapse incidence, and safety outcomes.

Use Cases

• Compare survival outcomes between age cohorts (60-70 vs. >70 years) based on overall survival and leukemia-free survival data.
• Analyze the association between treatment course frequency and patient outcomes based on the finding that >3 courses correlated with longer survival.
• Model competing risks of relapse and non-relapse mortality using the cumulative incidence data from the study.
• Investigate gene expression profiles related to long-term survival based on the transcriptomic analysis mentioned in the description.

Strengths

• Long-term follow-up with a median of 148.5 months, providing robust outcome data.
• Includes detailed clinical endpoints for 29 patients, such as complete remission rate (86.2%) and median overall survival (20.00 months).
• Data spans a substantial time range from April 2008 to June 2021.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is from a single-center study with 29 patients, which may limit generalizability.

Provenance

Source

Juan Liu via figshare.

Collection Method

Clinical data collected from a single-center study of patients receiving microtransplantation.

Time Range

April 2008 to June 2021, with follow-up through the study period.

Freshness

Last updated 2026-03-18 07:39:50; freshness should be verified.

Geography

Single-center study; specific location not provided.